The metastatic non-small cell lung cancer (mNSCLC) treatment landscape has vastly expanded over the past two decades as a ...

The following abstracts showcase the top cutting-edge research presented at the European Society for Medical Oncology (ESMO) ...

Announced encouraging initial Phase 2 data of BDTX-1535 in patients with recurrent EGFRm NSCLC with a broad spectrum of classical, non-classical, ...

another key risk is that the 2025 expansion cohort update in ovarian cancer could see a similar "sell the news" reaction to this year's ESMO data. One more concern is that I'm not sure the NSCLC ...

Studies reported at ESMO 2024 reveal new groups of women with ... advanced/metastatic nonsquamous non-small cell lung cancer (NSCLC), according to research presented today at the International ...

An expert discussed how liquid and tissue biopsies can help monitor treatment and detect potential resistance in patients ...

CStone Pharmaceuticals (HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced that the UK Medicines and ...

Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today reported financial results for the third quarter ...

Medscape Medical News, September 16, 2024 ESMO 2024 No DFS Benefit With Adjuvant Durvalumab in Early NSCLC The lack of a disease-free survival benefit with adjuvant durvalumab in early-stage ...

Merus’ zenocutuzumab is nearing FDA approval, and petosemtamab shows promise. Learn why MRUS stock could rise as the company ...

Welcome to the NovoCure Q3 2024 earnings conference call. [Operator instructions] Please be advised that today's conference ...

Detailed price information for Prelude Therapeutics Inc (PRLD-Q) from The Globe and Mail including charting and trades.